Evidence map›Paper›PMID 41321781›Full record

ArticleKidney diseases (Basel, Switzerland)

Application of Surface-Enhanced Raman Spectroscopy and Machine Learning Omics Techniques in the Progression Assessment of Autosomal Dominant Polycystic Kidney Disease.

Fangzheng Cui, Rui Cheng, Jing Xu, Cheng Xue, Huinan Yang, Zhiguo Mao

Abstract read
In one paragraph

Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fangzheng CuiDivision of Nephrology, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
Rui ChengDivision of Nephrology, Chinese People's Liberation Army 63680 Unit Hospital, Wuxi, China.
Jing XuDivision of Nephrology, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
Cheng XueDivision of Nephrology, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
Huinan YangDivision of Nephrology, Chinese People's Liberation Army 63680 Unit Hospital, Wuxi, China.
Zhiguo MaoDivision of Nephrology, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The progression evaluation of autosomal dominant polycystic kidney disease (ADPKD) is critical to the treatment strategy and prognosis prediction of the disease, but the current evaluation methods are time-consuming and costly. Methods: ADPKD patients were recruited in Shanghai Changzheng Hospital from February 2023 to October 2023. Based on the Mayo imaging classification (MIC) model, patients with different disease progression rates were classified into slowly progressive (SP) group (MIC 1A, 1B) or rapidly progressive (RP) group (MIC 1C, 1D, and 1E). The Raman spectra of urine samples from ADPKD patients were obtained by Surface-enhanced Raman spectroscopy (SERS) protocol and the characteristics of urine Raman spectra from SP and RP groups were analyzed. The ADPKD progression prediction model was constructed based on principal component analysis (PCA) and support vector machine (SVM). Results: After adjusting for age, gender, and renal function, there were differences in Raman intensity of the six major Raman peaks (758/794/1,184/1,288/1,346/1,385 cm Conclusions: Urinary SERS detection can distinguish RP ADPKD patients from SP ones noninvasively, conveniently and quickly, with reasonable accuracy, sensitivity, and specificity. SERS combined with machine learning omics techniques might be a novel method to evaluate the progression of ADPKD.

Indexed as

Autosomal dominant polycystic kidney diseaseDisease progressionPredictive modelsSurface-enhanced Raman spectroscopy

Identifiers

PMID41321781
PMCPMC12659602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.